Overview

Cutaneous mastocytosis encompasses a spectrum of presentations in which mast cells accumulate in the skin, often with clinically evident macules, papules, plaques, or nodular lesions, and variable mediator-related symptoms. Because disease expression differs widely between patients and can change over time with growth, sun exposure, friction, infection, or therapy, clinicians benefit from a structured, repeatable way to describe skin burden at a visit. The SCORMA (SCORing MAstocytosis) index was introduced as a semi-quantitative instrument that integrates three domains—extent, focal lesional activity, and patient-reported symptoms—into a single numeric summary suitable for serial assessment.

SCORMA was developed using the same general construction principles as the SCORAD index used in atopic dermatitis: separate ratings for involved surface area, lesion intensity on examination, and subjective complaints, then weighted combination into one score. The intent is not to replace histopathology, staging investigations, or mediator laboratory testing, but to provide a practical bedside and clinic-room measure that tracks how much skin is involved, how active representative lesions appear, and how symptomatic the patient has been during a defined recent interval.

When SCORMA is used

SCORMA is most informative when the clinical question is severity of cutaneous involvement and symptoms over time, for example when following urticaria pigmentosa–type patterns, more diffuse cutaneous involvement, or other forms where skin is the dominant organ of disease expression. It can support documentation for therapeutic trials, clinical photography series, and longitudinal care in pediatric and adult populations, provided the same rules are applied consistently between visits.

The score does not, by itself, establish the diagnosis of mastocytosis, distinguish indolent from aggressive disease categories, or quantify systemic mast cell burden. It should be interpreted together with age-appropriate evaluation for systemic involvement when clinically indicated, including symptoms, examination findings, and relevant laboratory data such as serum tryptase where appropriate to your practice setting.

Structure of the index: three parts (A, B, and C)

SCORMA separates three conceptually distinct aspects of the illness:

• Part A (extent) quantifies how much skin is clinically involved.
• Part B (intensity / activity) quantifies how inflamed or reactive a single chosen representative lesion appears on examination.
• Part C (subjective symptoms) quantifies recent symptom burden using visual analogue–style ratings across several domains.

Each part is scored on its own scale, then combined using a published weighting scheme so that lesional activity receives strong emphasis relative to extent and subjective complaints—reflecting the authors’ goal of capturing early changes in mast cell–driven skin activity during follow-up.

Part A: Extent of skin involvement

Extent is expressed as an approximate percentage of body surface area (BSA) involved by mastocytosis-associated skin changes. In practice, clinicians often estimate BSA using a body diagram (rule-of-nines–style partitioning) and sum the approximate contribution of affected regions. For very localized disease, the involved percentage may be small; for widespread involvement, it may approach complete skin involvement.

The original description notes that morphology can vary (solitary lesions versus more diffuse involvement). Marking the affected areas on a schematic figure helps standardize estimation between observers and reduces drift when the same patient is assessed at different time points. When lesions are few but large, careful mapping still allows a reasonable BSA estimate; when lesions are numerous but small, the cumulative surface may still be modest—both situations are compatible with SCORMA as long as the estimate reflects visually abnormal skin attributable to mastocytosis.

Part B: Lesional activity on a representative lesion

Part B does not sum findings across the entire body. Instead, the examiner selects one lesion that is typical in shape, color, and character for the patient’s overall eruption, then grades four features on a 0–3 scale each. The four items are:

• Pigmentation and erythema, reflecting color change and vascular/erythematous activity of the lesion.
• Vesiculation, capturing blister formation when present.
• Elevation, reflecting palpable infiltration or thickness of the lesion.
• Darier’s sign / reactivity, reflecting wheal-and-flare–type responses to rubbing or other local stimulation of the lesion, consistent with lesional mast cell releasability.

The original authors recommend choosing a lesion that is representative and, when possible, one that is relatively shielded from confounding factors such as chronic sun exposure (for example, a lesion on the back of the trunk may be preferable in some patients). Non-lesional skin nearby is used to interpret rubbing-related changes in context. The four subscores are summed, yielding a Part B subtotal from 0 to 12 (four items × three points maximum each).

Because Part B is multiplied strongly in the final formula, small changes in lesional activity can move the overall SCORMA score meaningfully—this is intentional for monitoring therapy aimed at reducing mast cell activation in the skin.

Part C: Subjective symptoms

Part C records the patient’s recent experience of illness impact and mediator-type symptoms. The original instrument uses five questions, each rated on a 0–10 scale (often implemented as a visual analogue scale in patients old enough to use one reliably). One question addresses daily inconvenience or global impact attributable to the disease; additional questions address symptoms that may relate to mast cell mediator release or mast cell accumulation, such as pruritus, flushing, gastrointestinal symptoms, and other constitutional or neurovascular complaints, depending on the exact wording on the published form used in your setting.

The authors specified a roughly three-week recall window for complaints prior to assessment. A window of this length aims to balance capture of persistent problems against noise from short-lived, unrelated symptoms. When comparing visits, using a similar recall window and similar question wording improves interpretability of change.

The five item scores are summed to produce C between 0 and 50. This domain intentionally contributes less than lesional activity in the final weighted index, while still ensuring that patients with major symptom burden are reflected in the total score.

Combining A, B, and C: the SCORMA formula

The published combination scales the three domains so that each can contribute comparably after transformation, while preserving a conceptual weighting where lesional activity is amplified. The practical formula used in the index is:

SCORMA = A/5 + 5B + 2C/5

where:

• A is extent from 0 to 100 (percent BSA).
• B is the Part B sum from 0 to 12.
• C is the Part C sum from 0 to 50.

The overall index ranges up to 100. At the maximum, a patient would have complete skin involvement, maximal lesional activity scores, and maximal subjective scores—an extreme pattern that is uncommon but defines the upper bound of the scale. More typical clinical values fall in intermediate ranges and should be interpreted in the context of phenotype, age, comorbidities, and concurrent medications (for example, antihistamines or other mast cell–targeted therapy) that may suppress symptoms without fully normalizing visible lesions.

Interpreting change over time

SCORMA is often used to describe both cross-sectional severity and change between visits. In research and some pediatric cohorts, investigators have examined whether a threshold change in the index (sometimes discussed on the order of roughly ten points, depending on cohort and endpoint) corresponds to clinically meaningful evolution. Such thresholds are not universal rules; they depend on the distribution of scores in the population studied and the clinical context. What matters in practice is consistency: same lesion selection rules, same BSA estimation approach, and same symptom time window when you intend to attribute change to disease or treatment.

Because Part B is weighted heavily, improvement driven primarily by reduced blistering, erythema, or reactivity may move the index even when post-inflammatory hyperpigmentation persists—an advantage when the clinical goal is to track active mast cell–driven inflammation.

Relationship to biomarkers and systemic evaluation

Serum tryptase and other mast cell–related laboratory measures may correlate with overall mast cell burden or systemic disease in some settings, but they do not replace a structured skin score. Studies have reported associations between SCORMA and biochemical markers in selected populations, supporting the idea that higher skin scores often align with greater overall disease activity—while also underscoring that skin scores and blood tests measure different constructs. In children especially, a reliable clinical index can be particularly valuable when phlebotomy is difficult or when the priority is frequent monitoring of visible disease.

Limitations and appropriate use

SCORMA requires training and consistency. Inter-rater agreement improves when examiners use the same definitions for each Part B item and agree on how to mark BSA. It is a clinical research and care support tool, not a stand-alone diagnostic criterion. It may not capture extracutaneous organ involvement, and it should not be used to delay necessary evaluation when systemic symptoms, rapid progression, or laboratory red flags are present.

When implementing SCORMA in electronic systems, ensure that the subjective questions match the validated wording used in your institution or trial protocol, and document whether medications that suppress itching or flushing were taken on the day of assessment, since symptom scores can be pharmacologically modulated.